Dual antagonists of platelet activating factor and histamine. Part 3. Synthesis, biological activity and conformational implications of substituted N-acyl-bis-arylcycloheptapiperazines

Bioorganic and Medicinal Chemistry Letters

Volumn 8, Issue 24, 1998, Pages 3469-3474

  Piwinski, John J ^a   Wong, Jesse K ^a   Green, Michael J ^a   Kaminski, James J ^a   Colizzo, Frank ^a   Albanese, Margaret M ^a   Ganguly, Ashit K ^a   Billah, M Motasim ^a   Anthes, John C ^a   West Jr , Robert E ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 ACETYL 4 (8 CHLORO 5,6 DIHYDRO 11H BENZO[5,6]CYCLOHEPTA[1,2 B]PYRIDIN 11 YLIDENE)PIPERIDINE; ANTIHISTAMINIC AGENT; N ACYL 4 (5,6 DIHYDRO 11H BENZO[5,6]CYCLOHEPTA[1,2 B]PYRIDIN 11 YLIDINE)PIPERAZINE; THROMBOCYTE ACTIVATING FACTOR ANTAGONIST; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; COMPUTER MODEL; CONFORMATIONAL TRANSITION; DRUG CONFORMATION; DRUG DETERMINATION; DRUG SYNTHESIS; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS;

HISTAMINE ANTAGONISTS; MOLECULAR CONFORMATION; PIPERAZINES; PLATELET ACTIVATING FACTOR; STEREOISOMERISM;

EID: 0032534820     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(98)00626-X     Document Type: Article

References (30)

1. nd National Meeting of the American Chemical Society, Division of Medicinal Chemistry, New York, NY, August 1991; Medi 161.
2. 2. (a) Beaven, M. A. Histamine: Its Role in Physiological and Pathological Processes; S. Karger: New York, 1978.
3. (b) Cooper, D. G.; Young, R. C.; Durant, G. J.; Ganellin, C. R. In Comp. Med. Chem.; Hansch, C., Ed.; Pergamon: New York, 1990; Vol. 3, pp 323-421.
4. 3. Eiser, N. M. Pharmacol. Therapeut. 1982, 17, 239.
5. 4. (a) Demopoulos, C. A.; Pinckard, R. N.; Hanahan, D. J. J. Biol. Chem. 1979, 254, 9355.
6. (b) Benveniste, J.; Tence, M.; Varenne, P.; Bidault, J.; Boullet, C.; Polonsky, J. C. R. Seances Acad. Sci. Ser. D 1979, 289, 1037.
7. 5. (a) Hanahan, D. J. Ann. Rev. Biochem. 1986, 55, 483.
8. (b) Braquet, P.; Tougui, L.; Shen, T. Y.; Vargaftig, B. B. Pharmacol. Rev. 1987, 39, 97.
9. (c) Braquet, P.; Rola-Pleszcynski, M. Immunol. Today 1987, 8, 345.
10. (d) Barnes, P. J.; Chung, K. F.; Page, C. P. J. Allergy Clin. Immunol. 1988, 81, 919.
11. 6. (a) Venuti, M. C. In Comp. Med. Chem.; Hansch, C., Ed.; Pergamon: New York, 1990, Vol. 3, pp 715-761.
12. (b) Braquet, P. CRC Handbook of PAF and PAF Antagonists; CRC: Boca Raton, 1991.
13. (c) Koltai, M.; Braquet, P. G. Clin. Rev. Allergy 1994, 12, 361.
14. (d) Summers, J. B.; Albert, D. H. In Adv. Pharmacol.; August, J. T.; Anders, M. W.; Murad, F.; Coyle, J., Eds.; Academic: San Diego, 1995, Vol. 32, pp 67-168.
15. 7. (a) Guinot, P. Clin. Rev. Allergy 1994, 12, 397.
16. (b) Koltai, M.; Guinot, P.; Hosford, D.; Braquet, P. G, In Adv. Pharmacol.; August, J. T.; Anders, M. W.; Murad, F.; Coyle, J., Eds.; Academic: San Diego, 1994, Vol. 28, pp 81-167.
17. (c) Kuitert, L. M.; Angus, R. M.; Barnes, N. C.; Barnes, P. J.; Bone, M. F.; Chung, K. F.; Fairfax, A. J.; Higenbotham, T. W.; O'Conner, B. J.; Piotrowska, B.; Rozniecki, J.; Uden, S.; Walters, E. H.; Willard, C. J. Am. J. Respir. Crit. Care Med. 1995, 151, 1331.
18. (d) Hozawa, S.; Haruta, Y.; Ishioka, S.; Yamakido, M. Am. J. Respir. Crit. Care Med. 1995, 152, 1198.
19. 8. (a) Piwinski, J. J.; Wong, J. K.; Green, M. J.; Ganguly, A. K.; Billah, M. M.; West, R. E.; Kreutner, W. J. Med. Chem. 1991, 34, 457.
20. (b) Wong, J. K.; Piwinski, J. J.; Green, M. J.; Ganguly, A. K.; Anthes, J. C.; Billah, M. M. Bioorg. Med. Chem. Lett. 1993, 3, 1073.
21. 9. Carceller, E.; Merlos, M.; Giral, M.; Balsa, D.; Almansa, C.; Bartroli, J.; Garcia-Rafanell, J.; Forn, J. J. Med. Chem. 1994, 37, 2697.
22. 10. Villani, F. J.; Daniels, P. J. L.; Ellis, C. A.; Mann, T. A.; Wang, K.-C. J. Heterocyclic Chem. 1971, 8, 73.
23. 11. The tricyclic mesylate was prepared in place of the corresponding chloride in the preparation of compound 5. The alkylation was conducted in situ to prevent solvolysis of the generated mesylate on workup.
24. 12. 8-Chloro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-one was prepared as described in Piwinski, J. J.; Wong, J. K.; Chan, T.-M.; Green, M. J.; Ganguly, A. K. J. Org. Chem. 1991, 34, 457.
25. 13. The preparation of bicyclic lactam 7 is shown below. We thank Dr. B. B. Bauer for his details in the conversion of 2-methylpyrazine to t-butyl 3-(piperazin-2-yl)propionate (unpublished results). (equation presented)
26. 14. (a) Billah, M. M.; Chapman, R. W.; Egan, R. W.; Gilcrest, H.; Piwinski, J. J.; Sherwood, J.; Siegel, M. I.; West, R. E.; Kreutner, W. J. Pharmacol. Exp. Ther. 1990, 252, 1090.
27. (b) Billah, M. M.; Egan, R. W.; Ganguly, A. K.; Green, M. J.; Kreutner, W.; Piwinski, J. J.; Siegel, M. I.; Vilani, F. J.; Wong, J. K. Lipids 1991, 26, 1172.
28. 15. The resolution was accomplished by repeated crystallization of 2a as the N-acetyl D-and L-leucine salts from acetonitrile/water. Subsequent acylation with acetic anhydride provided 3e and 3f with greater than 99% ee. Their absolute configurations were infered from the resolved S-enantiomer of 2a whose absolute configuration was determined by X-ray crystalligraphic analysis (McPhail, A. T., unpublished results).
29. 16. Young, S. D.; Baldwin, J. J.; Cochran, D. W.; King, S. W.; Remy, D. C.; Springer, J. P. J. Org. Chem. 1985, 50, 339.
30. 17. Kaminski, J. J.; Carruthers, N. I.; Wong, S.-C.; Chan, T.-M.; Billah, M. M.; Tozzi, S.; McPhail, A. T. Bioorg. Med. Chem. (submitted).